Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen.

Saved in:
Bibliographic Details
Title: Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen.
Authors: Helland T; Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Norway., Naume B; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway., Hustad S; Core Facility for Metabolomics, Department of Clinical Science, University of Bergen, Norway., Bifulco E; Core Facility for Metabolomics, Department of Clinical Science, University of Bergen, Norway., Kvaløy JT; Department of Mathematics and Physics, University of Stavanger, Norway.; Department of Research, Stavanger University Hospital, Norway., Saetersdal AB; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Norway., Synnestvedt M; Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Norway., Lende TH; Department of Surgery, Section for Breast and Endocrine Surgery, Stavanger University Hospital, Norway., Gilje B; Department of Oncology and Radiotherapy, Stavanger University Hospital, Norway., Mjaaland I; Department of Oncology and Radiotherapy, Stavanger University Hospital, Norway., Weyde K; Department of Oncology, Sykehuset Innlandet, Gjøvik, Norway., Blix ES; Immunology Research Group, Institute of Medical Biology, University of Tromsø, Norway.; Department of Oncology, University Hospital of North Norway, Tromsø, Norway., Wiedswang G; Department of GI-Surgery, Oslo University Hospital, Norway., Borgen E; Department of Pathology, Oslo University Hospital, Norway., Hertz DL; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA., Janssen EAM; Department of Pathology, Stavanger University Hospital, Norway.; Department of Bioscience and Environmental Engineering, University of Stavanger, Norway., Mellgren G; Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.; Department of Clinical Science, University of Bergen, Norway., Søiland H; Department of Clinical Science, University of Bergen, Norway.; Department of Oncology and Radiotherapy, Stavanger University Hospital, Norway.
Source: Molecular oncology [Mol Oncol] 2021 Apr; Vol. 15 (4), pp. 957-967. Date of Electronic Publication: 2020 Dec 14.
Publication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1878-0261
DOI:10.1002/1878-0261.12865